Contineum Therapeutics, Inc.

CTNM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001855175


None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $276.6M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: dilution, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Mar 5, 2026 240 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026
Last close	$9.40 2026-10-30; market equity $217.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease. We focus on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical-stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 76.8						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(1.9%)	(6.6%)		76.8	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 2.3						
Twelve-month failure probability	not computable	0.07%				
liabilities and a nearby cover-page share count are required at 2026-06-30						
Altman Z double-prime	19.89	(0.35)		2.8	748	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	27.50x	2.92x		1.8	829	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 2						
Net share issuance, one year	not computable	2.5%				
two annual share counts are required; found 1						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.3 months
Thin data	3 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	38.2%	7.3%	70
Distance from 52-week high	(46.6%)	(28.7%)	31
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(25.6%)	(1.0%)	21
Book value to price	1.10	0.28	87
Sales to price	0.00	0.30	0
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.11	(0.14)	70

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$14.7M
Operating cash flow, four quarters	-$53.0M
Months of runway	3.3
Days since last periodic filing	93 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	$7.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$60.0M	2025-12-31	2026-03-05	10-K	26-015165
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$55.3M	2025-12-31	2026-03-05	10-K	26-015165
3	assets	us-gaap:Assets	$276.6M	2025-12-31	2026-03-05	10-K	26-015165
4	assets	us-gaap:Assets	$212.8M	2024-12-31	2026-03-05	10-K	26-015165
5	current assets	us-gaap:AssetsCurrent	$267.9M	2025-12-31	2026-03-05	10-K	26-015165
6	current liabilities	us-gaap:LiabilitiesCurrent	$9.7M	2025-12-31	2026-03-05	10-K	26-015165
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$177.4M	2025-12-31	2026-03-05	10-K	26-015165
8	operating income	us-gaap:OperatingIncomeLoss	-$68.1M	2025-12-31	2026-03-05	10-K	26-015165
9	book equity	us-gaap:StockholdersEquity	$261.0M	2025-12-31	2026-03-05	10-K	26-015165
10	liabilities	us-gaap:Liabilities	$15.7M	2025-12-31	2026-03-05	10-K	26-015165
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2024-12-31	2025-03-06	10-K	25-006458
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$231,000	2025-12-31	2026-03-05	10-K	26-015165
13	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$323,000	2025-12-31	2026-03-05	10-K	26-015165
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$60.1M	2025-12-31	2026-03-05	10-K	26-015165
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-05	10-K	26-015165
16	current assets	us-gaap:AssetsCurrent	$206.4M	2024-12-31	2026-03-05	10-K	26-015165
17	current liabilities	us-gaap:LiabilitiesCurrent	$10.0M	2024-12-31	2026-03-05	10-K	26-015165
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,871,549	2025-02-28	2025-03-06	10-K	25-006458

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.